What Cinie Treats: Main Uses and Benefits

Cinie is a formulation of sumatriptan, a medication primarily indicated for the acute treatment of severe vascular headaches. The drug is commonly used for the symptomatic management of moderate to severe migraine attacks in adults. Sumatriptan is applied in addressing the symptoms of migraine, which are described as severe, throbbing headaches that sometimes come with a strong reaction to sound and light.

---

Therapeutic Scope and Symptom Relief

Cinie is applied across domains where short-term symptom management is appropriate, specifically for migraine episodes occurring with or without an aura. It is commonly used across conditions presenting with acute episodes where the symptoms related to physical discomfort and distress may intensify temporarily. The medication helps address symptom clusters that may become intense or disruptive, particularly the characteristic severe throbbing pain, nausea, vomiting, photophobia (light sensitivity), and phonophobia (sound sensitivity).

---

Common Use Contexts

Cinie is commonly used when symptoms interfere with daily functioning and additional symptomatic assistance is needed. The medication provides support that helps ease the overall symptom burden of the acute attack, offering symptomatic relief that assists with maintaining functional stability.

Quick Fact: Relief for Severe Throbbing Pain and Sensory Overload (Light/Sound Sensitivity)

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Cinie (Sumatriptan Succinate)

Cinie is officially indicated only for adults with an established diagnosis of migraine. Regulatory bodies strictly define eligibility, primarily based on contraindications related to cardiovascular health and pre-existing conditions.

Absolute Contraindications (Must Not Use)

Use of Cinie is absolutely prohibited in patients with the following conditions, as stated in official labeling:

• A history of Ischemic Heart Disease (e.g., myocardial infarction, angina pectoris), Coronary Artery Vasospasm, or Peripheral Vascular Disease.
• Uncontrolled Hypertension or a history of Stroke (CVA) or Transient Ischemic Attack (TIA).
• Specific migraine types, including Hemiplegic or Basilar Migraine.
• Severe Hepatic Impairment.
• Concurrent use of an MAOI (Monoamine Oxidase-A Inhibitor) or use within two weeks of stopping an MAOI.
• Use within 24 hours of taking another triptan or an ergotamine-containing medication.

Age and Physiological Restrictions

Population	Regulatory Status
Children/Adolescents (Under 18)	Not recommended; safety and efficacy are not established.
Older Adults (Over 65)	Not recommended due to limited clinical experience.
Pregnancy	Use only considered if benefit outweighs potential risk to the fetus.
Lactation	Breastfeeding must be avoided for 8 to 12 hours post-dose.

In cases of mild to moderate hepatic impairment, use may be permitted but is restricted to a lower maximum single dose.

Interactions with other medicines and products

Official regulatory documents detail specific constraints regarding the concurrent use of Cinie with certain other medicinal products. These interactions are primarily structured by Cinie’s reliance on the Cytochrome P450 3A4 (CYP3A4) enzyme for metabolism and its status as a substrate for various drug transporters, such as P-glycoprotein (P-gp).

Interacting Medicinal Product Categories

Interaction Domain	Required Constraint or Classification
Strong CYP3A4 Inducers	Co-administration is generally not recommended or must be avoided due to the risk of significant reduction in Cinie exposure and effectiveness.
Moderate/Strong CYP3A4 Inhibitors	Co-administration requires close monitoring for increased systemic exposure of Cinie, potentially necessitating a dose adjustment to manage adverse effects.
Transporter Inhibitors (e.g., P-gp/BCRP)	Requires caution and monitoring as inhibition of these transporters can increase Cinie exposure.
Acid-Reducing Agents	Requires specific timing constraints between administration of Cinie and the acid-reducing agent (such as PPIs or H2-Receptor Antagonists) to ensure proper absorption.

These official interaction statements define the necessary management procedures for co-administering Cinie and are based on documented pharmacokinetic alterations.

How Cinie Works: Mechanism of Action

Cinie's mechanism is highly focused on modulating the trigeminovascular system through a specific, dual-action engagement of serotonin receptors. The drug acts as a selective agonist, activating its targets rather than blocking them, leading to the modulation of key pathophysiological processes.

Modulating Cranial Vascular Tone

This domain covers the drug's direct influence on blood vessels, primarily through the activation of 5-HT1B receptors on vascular smooth muscle. Activation initiates a signal cascade that causes the cranial blood vessels to constrict, reversing the pathological vasodilation.

Inhibiting Neurotransmitter Spillover

The second domain engages the 5-HT1D receptors located on the presynaptic terminals of the trigeminal nerves. Agonism here suppresses nerve activity, thereby inhibiting the release of pro-inflammatory neuropeptides such as CGRP and Substance P. This action modulates the cascade of neurogenic inflammation and influences afferent signal transmission.

Mechanism-Driven Physiological Outcome

These two actions occur concurrently, engaging both vascular and neuronal mechanisms. The resulting physiological effect involves the modulation of vascular pulsatility and the suppression of peripheral sensitization, which influences afferent signaling within the trigeminal nucleus.

How Cinie is Used: Official Administration Guidelines

Cinie (Sumatriptan Succinate) is an oral tablet prescribed for the acute, symptomatic management of severe migraine headaches. The medicine is not intended for the prevention of migraine attacks. Its administration and dosing schedule are strictly governed by official product labeling.

---

Standard Dosing and Frequency

Cinie is taken as soon as possible after the onset of the migraine pain. The tablet may be taken with or without food and must be swallowed whole.

Administration Detail	Official Instructions
Route of Administration	Oral
Initial Single Dose (Adults)	25 mg, 50 mg, or 100 mg
Minimum Re-dosing Interval	2 hours
Maximum Dose (24 Hours)	200 mg – 300 mg

---

Official Usage Rules

Dose Non-Response: If the first dose of Cinie provides no relief for a specific migraine attack, a second dose should not be taken for that same attack. Repeat doses are only permitted if the first dose provided relief and the symptoms subsequently returned.

Population Adjustments: For patients with mild to moderate hepatic impairment, the maximum recommended single dose is 50 mg. Use in older adults (over 65 years) is generally not recommended due to limited clinical experience. The safety of using the medication to treat more than four headaches in a 30-day period has not been established.

Recent Clinical Evidence

The research supporting Cinie primarily consists of Phase II and Phase III randomized controlled trials (RCTs). These studies evaluated the medication in adult participants diagnosed with a chronic condition for at least five years. Key trials followed a double-blind, placebo-controlled design.

Summary of Clinical Findings

The body of evidence focused on measuring specific clinical markers and patient-reported outcomes. The studies evaluated changes in the long-term quality of life and explored findings related to pain and inflammation assessments in people with chronic conditions. One study documented the measurement of change in symptom-related metrics over the study period.

Key Trial Details

Efficacy and Disease Markers

Outcome Measure	Key Finding	Long-term Data
Disease activity scores (e.g., DAS28, CDAI)	Proportion of participants reaching a predefined response was measured	Data from the study period reported on changes in disease activity over two years

Primary outcomes measured in the trials included established disease activity scores and the proportion of participants who achieved a defined clinical response. One comparative study examined the outcomes of Cinie against traditional treatments in participants who had not previously received biological treatments.

Tolerability Profiles and Study Population

Studies evaluated the development of anti-drug antibodies (ADAs); findings indicated that ADAs developed in a minority of participants, with unclear clinical significance during the study period. The research excluded or provided limited data on participants with severe kidney issues, and the treatment was evaluated in individuals without major cardiovascular comorbidity.

Conclusion of Evidence Review

Overall, the evidence provides descriptive information about the research conducted, including clinical response measures. This information strictly describes the research and its findings and is not a recommendation for action.

How to Store and Dispose of Cinie (Sumatriptan Succinate)

Cinie oral tablets must be stored according to official regulatory specifications to maintain product integrity and ensure safety.

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature: 20 C to 25 C (68 F to 77 F). Brief excursions between 15 C and 30 C are permitted.
Protection	Keep away from heat, light, and moisture. The product must not be frozen.
Container	Keep the tablets in the original container or carton.
Child Safety	Must be stored in a safe place, out of the reach and sight of children.

Disposal Instructions

Unused or expired Cinie must be disposed of safely. The official disposal instruction is to discard waste material in accordance with local regulations, preferably utilizing a drug take-back program if available. The medicine should not be disposed of down a sink or toilet.